Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
CONCLUSIONS: Boosting KYNA levels, through interference with the KP enzymes or through application of prodrugs/analogs with high bioavailability and potency, is a promising clinical approach. The use of KYNA, alone or in combination with other compounds precisely influencing specific populations of neurons, is awaiting to become a significant therapy for neurodegenerative disorders.PMID:34862742 | DOI:10.1111/cns.13768
Source: CNS Neuroscience and Therapeutics - Category: Neuroscience Authors: Aleksandra Ostapiuk Ewa M Urbanska Source Type: research
More News: Alzheimer's | Brain | Huntington's Disease | Neurology | Neuroscience | Parkinson's Disease